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POSTOPERATIVE ATRIAL FIBRILLA-tion or flutter (AF) occurs inapproximately 1 of 3 patientsundergoing cardiac surgery,
and rates of this complication remain
unchanged, even with advances in sur-
gical techniques, anesthetic proce-
dures, and perioperative care.1,2 Post-
operative AF can cause hemodynamic
instability or symptoms requiring car-
dioversion or escalation of supportive
therapies and also can cause renal and
neurologic complications. Antiarrhyth-
mic and anticoagulant drugs are often
required, both in-hospital and after dis-
charge, and can cause adverse effects
including bleeding. Postoperative AF at
discharge can cause palpitations, fa-
tigue, and decreased exercise toler-
ance. Patients with postoperative AF
also have higher long-term mortal-
ity,1,2 at least partly attributable to em-
bolic stroke.3
Postoperative AF is also associated
with greater intensive care unit stays,
total hospital stays, and total hospital
costs.4-6 Even with use of -blockers
and amiodarone, approximately 1 of 4
patients still develop postoperative
AF, with inconsistent improvements
in mortality or resource utilization.7
Hence, new therapies are needed to
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Context Postoperative atrial fibrillation or flutter (AF) is one of the most common
complications of cardiac surgery and significantly increases morbidity and health care
utilization. A few small trials have evaluated whether long-chain n-3-polyunsaturated
fatty acids (PUFAs) reduce postoperative AF, with mixed results.
Objective To determine whether perioperative n-3-PUFA supplementation re-
duces postoperative AF.
Design, Setting, and Patients The Omega-3 Fatty Acids for Prevention of Post-
operative Atrial Fibrillation (OPERA) double-blind, placebo-controlled, randomized clini-
cal trial. A total of 1516 patients scheduled for cardiac surgery in 28 centers in the
United States, Italy, and Argentina were enrolled between August 2010 and June 2012.
Inclusion criteria were broad; the main exclusions were regular use of fish oil or ab-
sence of sinus rhythm at enrollment.
Intervention Patients were randomized to receive fish oil (1-g capsules containing
840 mg n-3-PUFAs as ethyl esters) or placebo, with preoperative loading of 10 g
over 3 to 5 days (or 8 g over 2 days) followed postoperatively by 2 g/d until hospital
discharge or postoperative day 10, whichever came first.
Main Outcome Measure Occurrence of postoperative AF lasting longer than 30
seconds. Secondary end points were postoperative AF lasting longer than 1 hour, re-
sulting in symptoms, or treated with cardioversion; postoperative AF excluding atrial
flutter; time to first postoperative AF; number of AF episodes per patient; hospital uti-
lization; andmajor adverse cardiovascular events, 30-daymortality, bleeding, and other
adverse events.
Results At enrollment, mean age was 64 (SD, 13) years; 72.2% of patients were
men, and 51.8% had planned valvular surgery. The primary end point occurred in 233
(30.7%) patients assigned to placebo and 227 (30.0%) assigned to n-3-PUFAs (odds
ratio, 0.96 [95% CI, 0.77-1.20]; P=.74). None of the secondary end points were sig-
nificantly different between the placebo and fish oil groups, including postoperative
AF that was sustained, symptomatic, or treated (231 [30.5%] vs 224 [29.6%], P=.70)
or number of postoperative AF episodes per patient (1 episode: 156 [20.6%] vs 157
[20.7%]; 2 episodes: 59 [7.8%] vs 49 [6.5%];3 episodes: 18 [2.4%] vs 21 [2.8%])
(P=.73). Supplementation with n-3-PUFAs was generally well tolerated, with no evi-
dence for increased risk of bleeding or serious adverse events.
Conclusion In this large multinational trial among patients undergoing cardiac sur-
gery, perioperative supplementation with n-3-PUFAs, compared with placebo, did not
reduce the risk of postoperative AF.
Trial Registration clinicaltrials.gov Identifier: NCT00970489
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prevent postoperative AF and its asso-
ciated morbidity and health care
costs.
The accumulated evidence from ob-
servational studies and clinical trials
suggests that habitual intake of fish or
fish oil reduces risk of coronary death,
possibly related to fewer primary ven-
tricular arrhythmias.8,9 Experimental
evidence supports direct and indirect
antiarrhythmic effects of long-chain n-3
polyunsaturated fatty acids (n-3-
PUFAs) in fish oil, especially in the set-
ting of acute ischemia.8 Yet effects of
n-3-PUFAs on atrial arrhythmias such
as postoperative AF remain uncertain.
In experimental studies and short-
term clinical trials, n-3-PUFAs favor-
ably influence several risk factors for
AF.8,10-12 Only small trials of n-3-
PUFA supplementation to prevent post-
operative AF have been performed, with
mixed results.13
We designed and implemented the
Omega-3 Fatty Acids for Prevention of
Post-operative Atrial Fibrillation
(OPERA) trial to determine whether
perioperative administration of oral n-3-
PUFAs reduces postoperative AF in pa-
tients undergoing cardiac surgery.
METHODS
Study Design and Patients
The OPERA trial was an investigator-
initiated, double-blind, placebo-
controlled, randomized clinical trial
conducted in 28 centers in the United
States, Italy, and Argentina to test the
primary hypothesis that perioperative
n-3-PUFA supplementation reduces the
occurrence of postoperative AF in 1516
patients undergoing cardiac surgery.
The detailed methods have been pub-
lished.14 The design was pragmatic to
maximize practical application and gen-
eralizability to real-world patients and
clinical care.
Inclusion criteria were broad (eTable
1, available at http://www.jama.com),
including age 18 years or older, being
scheduled for cardiac surgery on the fol-
lowing day or later, and presence of si-
nus rhythm on the screening electro-
cardiogram (ECG). Exclusions were
absence of sinus rhythm at screening,
regular use of fish oil, known allergy
or intolerance to fish oil or olive oil,
being currently pregnant, existing or
planned cardiac transplant or use of
ventricular assist device, or being un-
able or unwilling to provide informed
consent. Use of chronic or prophylac-
tic antiarrhythmic drugs, history of
prior AF, and planned AF ablation were
not exclusions, given the similar or
higher risk of postoperative AF in these
patients and no known biologic inter-
action that might reduce efficacy of n-3-
PUFAs in such patients.
The study was approved by the hu-
man subjects committees of all partici-
pating institutions and conducted ac-
cording to international standards of
Good Clinical Practice (FDA Title 21
part 312, International Conference on
Harmonization guidelines). All pa-
tients provided written informed con-
sent.
Intervention
Patients were block randomized to
receive n-3-PUFAs; each 1-g capsule
contained at least 840 mg of eicosap-
entaenoic acid (EPA) (approximately
465 mg) plus docosahexaenoic acid
(DHA) (approximately 375 mg) as
ethyl esters (Omacor; Pronova
BioPharma, Norway) or matched
placebo (olive oil) by means of
computer-generated numbers, strati-
fied by enrolling medical center and
planned valve surgery (yes/no). Study
drugs were prepared in identical-
appearing capsules specially coated to
minimize taste differences. All investi-
gators, patients, and clinicians were
blinded to treatment assignment.
Patients received a total preopera-
tive loading dose of 10 g divided over
3 to 5 days (or 8 g divided over 2 days),
including the morning of surgery.14 For
each patient, the loading dose was di-
vided over the maximum number of
days possible, based on the dates of en-
rollment and planned surgery. Flex-
ibility in the loading days included in
the regimen maximized generalizabil-
ity by allowing enrollment of most pa-
tients undergoing cardiac surgery, in-
cluding those scheduled as early as the
next day. Following cardiac surgery, pa-
tients received 2 g/d until hospital dis-
charge or postoperative day 10, which-
ever occurred sooner, at which time
administrative censoring occurred for
in-hospital follow-up.
The dosing was selected to balance
potential efficacy vs patient intoler-
ance and risk. Cohort studies suggest
that n-3-PUFAs reduce risk of pri-
mary ventricular arrhythmias at low
doses, eg, 250 to 500 mg/d of EPA plus
DHA.8 Similar low dietary doses have
been associated with lower incident AF
in ambulatory adults,15 and, in 1 small
open-label trial, a 10-g preoperative
loading dose over 5 days followed by
2 g/d postoperatively reduced postop-
erative AF.16 Supplementation with n-3-
PUFAs alters circulating and tissue lev-
els of EPA and DHA within days.17
Because n-3-PUFAs persist in tissues for
several days, a loading dose also pro-
vides some buffer in patients who might
not tolerate oral medications for sev-
eral days after surgery. Higher doses
could increase patient dyspepsia as well
potential concern among treating phy-
sicians for risks such as bleeding.
For patients unable to tolerate oral
medications postoperatively, the study
drug could be administered via poly-
vinyl chloride–free nasogastric or gas-
tric tube if present for clinical indica-
tions or otherwise as soon as the patient
was tolerating oral medications. Ad-
herence was monitored by capsule
count for outpatient loading and by hos-
pital records for inpatient administra-
tion as well as by changes in plasma
phospholipid n-3-PUFA levels (see
“Covariates,” below).
Centers were encouraged to use con-
tinuous electrocardiographic monitor-
ing for at least 5 days post surgery.
Twelve-lead ECGs were recommended
daily and more frequently at the discre-
tion of the treating physicians for symp-
toms or clinically suspected arrhyth-
mia. Clinical data (eg, onset time,
symptoms, treatments, duration) and
confirmatory rhythm strips or 12-lead
ECGs were collected for all postopera-
tive arrhythmias of at least 30 seconds’
duration, including postoperative AF
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and other tachyarrhythmias (eTable 2).
Data on at least the first 3 suspected epi-
sodes of postoperative AF were col-
lected for each patient. All other treat-
ments, including surgical and anesthetic
procedures, medications including regu-
lar or prophylactic antiarrhythmic drugs,
and treatment of arrhythmias re-
mained entirely at the discretion of the
physicians caring for the patient. Cur-
rent best-practice guidelines for preven-
tion of postoperative AF were strongly
recommended to all centers.18
End Points
The primary end point was the occur-
rence of postoperative AF of at least 30
seconds’ duration and documented by
rhythm strip or 12-lead ECG (eTable
2). Secondary AF end points included
postoperative AF that was sustained
(1 hour), symptomatic, or treated
with pharmacological or electrical car-
dioversion; postoperative AF exclud-
ing atrial flutter; time to first postop-
erat ive AF; and the number of
postoperative AF episodes per pa-
tient. The OPERA trial also evaluated
the total number of in-hospital days in
which any postoperative AF, includ-
ing sustained postoperative AF, was
present and the proportion of in-
hospital days free of any postoperative
AF. All potential episodes of postop-
erative AF and other tachyarrhyth-
mias were reviewed and adjudicated by
a centralized events committee of car-
diac electrophysiologists. Additional
end points included resource utiliza-
tion, major adverse cardiovascular
events, arterial thromboembolism, and
30-day mortality.
Safety Evaluation
Safety outcomes included adverse
events and bleeding assessed by
24-hour chest tube output following
surgery, total packed red blood cell
transfusions, and composite bleeding
indices (eTable 2). Potential adverse
events were recorded and reported to the
steering committee and the indepen-
dent data and safety monitoring board
(DSMB), as well as to the US Food and
Drug Administration, European Medi-
cines Agency, and Argentina National
Administration of Drugs, Foods and
Medical Devices. The steering commit-
tee monitored the progress of the trial,
and the DSMB monitored both scien-
tific integrity and patient safety through-
out the trial and could recommend ter-
mination or other trial modifications at
any time. In July 2011, the DSMB re-
viewed a detailed interim analysis pre-
pared by a biostatistician not affiliated
with the trial and recommended study
continuation.
Covariates
Standardized data were collected on
demographics, risk factors, major
comorbid conditions, past medical
and surgical history, anthropometry,
lifestyle habits, outpatient and inpa-
Figure 1. Screening, Randomization, and Follow-up
758 Included in primary analysis 758 Included in primary analysis
704 Completed 30-d follow-up 717 Completed 30-d follow-up
3154 Patients assessed for
eligibility
708 Discharged from hospitalb 722 Discharged from hospitalb
727 Underwent cardiac surgery 735 Underwent cardiac surgery
10 Withdrew consent
9 Died
9 Withdrew consent
4 Died
4 Died 4 Died
1 Withdrew consent
758 Randomized to receive
placebo
758 Randomized to receive
n-3-PUFAs
15 Withdrew consent
2 Died
1 Emergency surgery
2 Violation of
recruitment criteria
11 Surgeon or patient
decision not to
proceed with surgery
16 Withdrew consent
1 Violation of
recruitment criteria
6 Surgeon or patient
decision not to
proceed with surgery
1638 Excluded
1544 Did not meet inclusion criteriaa
663 Not in sinus rhythm on current ECG
473 Regular use of fish oil within past 4 wk
385 Unwilling to provide written informed consent
90 Unable to provide written informed consent
 58 Planned or prior heart transplant/LVAD
52 Scheduled for cardiac surgery on that day
94 Met eligibility criteria but excluded for other reasons
46 Refused
26 Organizational challenges or delays
3 Enrolled in another research protocol
19 Other or missing
46 Known allergy or intolerance to fish oil
or olive oil
1516 Randomized
No patients were lost to follow-up. ECG indicates electrocardiogram; LVAD, left-ventricular assist device; n-3-
PUFA, omega-3 polyunsaturated fatty acid.
aPatients could be excluded based on more than 1 criterion; all are listed.
b Includes patients (102 placebo; 104 n-3-PUFA) censored at postoperative day 10 rather than discharged.
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tient medications, and laboratory
measures. Details of the surgical and
anesthetic procedure were recorded.
Daily follow-up and discharge infor-
mation, including cardiac drug
use and bleeding end points, was
recorded. In a subset of 523 patients
from centers participating in biologic
studies, samples of EDTA plasma
were drawn at enrollment and on the
morning of cardiac surgery, stored at
−70C, and shipped on dry ice to a
central repository for long-term stor-
age at −80C. Levels of plasma phos-
pholipid n-3-PUFAs (EPA plus docos-
apentaenoic acid [DPA] plus DHA)
were measured as a percentage of
total fatty acids at the Fred Hutchin-
son Cancer Research Center (Seattle,
Washington) using established meth-
ods,19 with coefficients of variation of
less than 3% for EPA, DPA, and DHA.
Statistical Analysis
All analyses were prespecified prior to
closing of the study database. The main
analysis was by intention-to-treat, in-
cluding all patients according to treat-
ment assigned at randomization. The
primary end point was evaluated using
Pearson 2 (for 2 groups, equivalent to
binomial test of proportions). Logistic
regression was used to determine the
odds ratio and 95% CI and for second-
ary multivariate analyses and tests of in-
teraction. Survival analyses and the log-
rank test were used for incident
postoperative AF and major adverse car-
diovascular events, arterial thrombo-
embolism, and mortality. In all analy-
ses, missing values were not imputed,
and only observed values were used. All
patients who withdrew or died were in-
cluded in all analyses until their date
of death or withdrawal. A sensitivity
analysis considered all patients who
died, withdrew, or were otherwise lost
to follow-up before hospital discharge
or postoperative day 10, whichever
came first, as having had postopera-
tive AF.
Planned enrollment of 1516 pa-
tients provided 90% power to detect a
25% reduction in postoperative AF with
2-tailed =.05, based on an estimated
30% event rate in controls and 5% drop-
out. The control event rate was esti-
mated from prior studies of postopera-
tive AF,1,2 and the 25% reduction as a
reasonable minimum clinically mean-
ingful risk reduction that was also con-
Table 1. Baseline Characteristics of the OPERA Participants, According to Treatment Assignment
Characteristic
No. (%)
P
Valuea
Placebo
(n = 758)
n-3-PUFAs
(n = 758)
Age, mean (SD), y 63.6 (12.4) 63.8 (12.6) .75
Men 543 (71.6) 551 (72.7) .65
Planned valve surgeryb 389 (51.3) 396 (52.2) .72
Current smoking 96 (13.0) 99 (13.5) .78
Body mass index, mean (SD)c 28.4 (5.9) 28.1 (5.4) .30
Waist circumference, mean (SD), cm 99.4 (13.5) 98.8 (14.1) .16
Hypertension 563 (74.9) 572 (76.2) .56
Dyslipidemia 477 (64.1) 460 (61.7) .33
Diabetes mellitus 199 (26.3) 194 (25.7) .78
Chronic obstructive pulmonary disease 90 (11.9) 80 (10.6) .42
Chronic renal failure 52 (6.9) 44 (5.8) .40
Coronary heart diseased 288 (38.0) 297 (39.2) .64
Prior myocardial infarction 178 (23.6) 188 (25.0) .55
Prior percutaneous coronary intervention 99 (13.1) 80 (10.6) .13
Prior cardiac surgery 48 (6.3) 45 (5.9) .75
Coronary bypass 18 (2.4) 17 (2.2) .86
Valve surgery 27 (3.6) 23 (3.0) .57
Other cardiac surgery 12 (1.6) 13 (1.7) .84
Prior arrhythmias 99 (13.3) 92 (12.5) .64
Atrial fibrillation 62 (8.4) 52 (7.1) .35
Other supraventricular tachycardia 8 (1.1) 12 (1.6) .40
Ventricular tachycardia or fibrillation 5 (0.7) 7 (0.9) .51
Other 33 (4.5) 22 (3.0) .14
Congestive heart failure 212 (28.0) 204 (27.0) .66
NYHA class
I 10 (1.3) 4 (0.5)
II 104 (13.7) 100 (13.2)
III 61 (8.1) 77 (10.2)
.16
IV 12 (1.6) 8 (1.1)
Not available 25 (3.3) 15 (2.0)
Ejection fraction, mean (SD), % 56.8 (11.3) 56.6 (11.4) .67
Left atrial diameter, mean (SD), mm 42.2 (7.6) 42.1 (7.8) .77
Prior implantable cardiodefibrillator 11 (1.5) 5 (0.7) .13
Prior pacemaker 9 (1.2) 11 (1.5) .54
Prior cardiac resynchronization therapy 0 1 (0.1) .50
Prior AF ablation 6 (0.8) 6 (0.8) .99
EuroSCORE, median (IQR)e
Logistic 3.6 (1.8-7.2) 3.7 (2.0-7.5) .64
Additive 5.0 (3.0-7.0) 5.0 (3.0-7.0) .68
Abbreviations: AF, atrial fibrillation; EuroSCORE, European System for Cardiac Operative Risk Evaluation; IQR, interquartile
range; n-3-PUFA, omega-3 polyunsaturated fatty acid; NYHA, New York Heart Association; OPERA, Omega-3 Fatty
Acids for Prevention of Post-operative Atrial Fibrillation.
aDifferences between treatment groupswere evaluated using unpaired t tests orWilcoxon rank-sum tests, as appropriate,
for continuous variables; and Pearson 2 (or Fisher exact tests for cells10) for categorical variables.
bOf the 756 patients who underwent valve surgery, 522 (69.0%) underwent aortic valve surgery, 195 (28.8%) mitral valve
surgery, 30 (4.0%) aortic and mitral valve surgery, and 9 (1.2%) other valve surgery; see eTable 3.
cCalculated as weight in kilograms divided by height in meters squared.
dPrior myocardial infarction, coronary revascularization, or angina.
e Incorporates 17 predictive factors about the patient, comorbid conditions, and the planned operation to calculate the risk
of 30-day postoperative mortality.20,21 The EuroScore can be calculated using either a logistic or additive model, with
higher scores indicating higher risk. The logistic model (theoretical range, 0-100) provides a score that is directly equiva-
lent to the predicted 30-day mortality (percent). The additive model (theoretical range, 0-39) is a simplified version that
approximates the predicted 30-day mortality. Values for the 17 individual components of these scores were also well
balanced between treatment groups (eTable 4).
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siderably more conservative than in ear-
lier studies.16
Secondary multivariable analyses
were prespecified, adjusted for age, sex,
country, type of cardiac surgery, use of
perioperative antiarrhythmic drugs, and
any baseline characteristics that were
statistically different between treat-
ment groups at P	 .15. In addition to
intention-to-treat analyses, we also sec-
ondarily evaluated the surgical popu-
lation (the subset of patients who were
enrolled without protocol violation, re-
ceived at least 1 dose of study drug, and
underwent cardiac surgery) and the ad-
herent (on-treatment) population (the
subset of the surgical population who
took 80% of their loading dose [or
75% for patients who received study
drug loading over 2 days] and also
80% of all assigned study capsules
over the course of the study until the
onset of the primary end point or the
end of assigned treatment, whichever
occurred first).
We hypothesized stronger efficacy of
treatment in 3 prespecified sub-
groups: those with lower habitual con-
sumption of oily fish (2 vs 2 serv-
ings/wk), lower plasma phospholipid
n-3-PUFA levels at enrollment (4%
vs 4%, also evaluated continuously
using semiparametric restricted cubic
splines), and greater number of actual
study drug loading days (0 to 5 actual
days, evaluated ordinally). Interaction
by these subgroups was evaluated at
2-tailed =.05. Other subgroup analy-
ses (eAppendix), also prespecified but
considered exploratory (ie, no hypoth-
esized direction of interaction) and
based on lower statistical power to de-
tect interaction, were evaluated at
2-tailed = .10. Analyses were per-
formed using Stata version 12.1 (Col-
lege Station, Texas).
RESULTS
Between August 2010 and June 2012,
1516 patients were enrolled (FIGURE 1).
Formal screening logs were main-
tained, and 48% of all screened pa-
tients and 94% of all eligible patients
were enrolled. Ineligible patients were
most often excluded because they were
not in sinus rhythm (40.5%), were tak-
ing fish oil (28.9%), or were unwilling
to provide informed consent (23.5%).
At baseline, mean age was 64 (SD, 13)
years; 1094 patients (72.2%) were men,
and cardiovascular risk factors were
common (TABLE 1 andTABLE 2). Valve
surgery was planned in 785 patients
(51.8%); of the 756 who underwent
valve surgery, 522 (69.0%) under-
went aortic valve surgery, 195 (25.8%)
mitral valve surgery, 30 (4.0%) aortic
and mitral valve surgery, and 9 (1.2%)
other valve surgery. The median logis-
tic EuroSCORE (European System for
Cardiac Operative Risk Evaluation)20,21
value was 3.7 (interquartile range
[IQR], 1.9-7.4). The treatment groups
had evenly matched characteristics.
Following randomization and study
drug loading, 96.4% of patients under-
went cardiac surgery. Details of the sur-
gical procedure and postoperative medi-
cations are reported in eTable 3.
Postoperative medications were simi-
lar by treatment group and included
-blockers in 76.9% of patients over-
all and amiodarone in 36.9% after car-
diac surgery.
The primary end point occurred in
233 patients (30.7%) in the placebo
group and 227 (30.0%) in the n-3-
PUFA group (P=.74). None of the sec-
ondary postoperative AF end points or
other arrhythmias were significantly dif-
ferent by treatment group (TABLE 3 and
FIGURE 2). In-hospital major adverse
cardiovascular events occurred in 20 pa-
tients (2.6%) in the placebo group and
in 13 (1.7%) in the n-3-PUFA group
(P=.18). At 30 days, 15 patients (2.0%)
in the placebo group and 8 (1.1%) in
the n-3-PUFA group had died (P=.14).
Incidence of the secondary end points
of arterial thromboembolism and arte-
rial thromboembolism or death was sig-
nificantly lower in the n-3-PUFA group
(P=.047 and P=.01, respectively). The
total number of days in the intensive
care unit or coronary care unit, of te-
Table 2. Baseline Medication Use of the OPERA Participants, According to Treatment
Assignment
Medication
No. (%)
P
Valuea
Placebo
(n = 758)
n-3-PUFAs
(n = 758)
-Blocker 433 (57.2) 444 (58.6) .57
Statin 427 (56.3) 436 (57.5) .64
ACE inhibitor 274 (36.2) 284 (37.5) .59
Angiotensin II receptor blocker 103 (13.6) 114 (15.0) .42
Calcium channel blocker 122 (16.1) 132 (17.4) .49
Loop diuretics 168 (22.2) 190 (25.1) .19
Aldosterone antagonists 37 (4.9) 28 (3.7) .25
Digitalis 2 (0.3) 14 (1.9) .004
Antiplatelets or anticoagulants 473 (62.4) 455 (60.0) .34
Antiplatelets 407 (53.7) 389 (51.3) .36
Aspirin 396 (52.2) 378 (49.9) .36
Clopidogrel 53 (7.0) 62 (8.2) .38
Ticlopidine 5 (0.7) 4 (0.5) .99
Other 5 (0.7) 4 (0.5) .99
Anticoagulants 129 (17.0) 121 (16.0) .58
Warfarin 24 (3.2) 17 (2.2) .27
Heparin 105 (13.9) 103 (13.6) .88
Other 1 (0.1) 1 (0.1) .99
Antiarrhythmics
Amiodarone 28 (3.7) 30 (4.0) .78
Otherb 12 (1.6) 14 (1.9) .69
Abbreviations: ACE, angiotensin-converting enzyme; OPERA, Omega-3 Fatty Acids for Prevention of Post-operative Atrial
Fibrillation.
aDifferences between treatment groups were evaluated using Pearson 2 (or Fisher exact tests for cells10).
b Including flecainide, propafenone, quinidine, disopyramide, or sotalol.
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lemetry monitoring, or of total hospi-
tal stay did not differ significantly be-
tween groups.
Most postoperative AF events oc-
curred between postoperative days 1 to
4, peaking on day 2 (eFigure). Among
all 661 episodes, 353 lasted less than 1
day (median duration, 3.3 hours [IQR,
1.2-7.7 hours]), and 308 lasted 1 day
or longer (median duration, 1.0 day
[IQR, 1.0-3.0 days]). There were no sig-
nificant differences in duration by treat-
ment (Wilcoxon rank-sum P= .25).
Thirty-two patients in the placebo
group and 30 in the n-3-PUFA group
were discharged with persistent post-
operative AF.
In sensitivity analyses defining all
patients who died or withdrew con-
sent as having had postoperative AF,
266 patients (35.1%) in the placebo
group and 250 (33.0%) in the n-3-
PUFA group developed postoperative
AF (P=.39). Findings were similar in
multivariable analyses adjusted for
age, sex, country, type of cardiac sur-
gery, use of perioperative antiarrhyth-
mic drugs, and baseline characteris-
t i c s d i f f e r ing be tween groups
(eAppendix).
Table 3. Primary and Secondary Study Outcomes in OPERA, According to Treatment Assignment.
Outcome
No. (%)
OR or HR
(95% CI)a
P
Valueb
Placebo
(n = 758)
n-3-PUFAs
(n = 758)
Any first postoperative AF, primary end pointc 233 (30.7) 227 (30.0) 0.96 (0.77-1.20) .74
Postoperative AF, secondary end points
Sustained, symptomatic, or treated postoperative AFd 231 (30.5) 224 (29.6) 0.96 (0.77-1.19) .70
Postoperative AF excluding fluttere 220 (29.0) 217 (28.6) 0.98 (0.79-1.23) .87
No. of postoperative AF episodes
1 156 (20.6) 157 (20.7)
2 59 (7.8) 49 (6.5)
NA .73
3 18 (2.4) 21 (2.8)
Total in-hospital days with any postoperative AF, mean (SD)f 2.75 (2.1) 2.84 (2.1) NA .58
Proportion of in-hospital days free of any postoperative AF, % 89.0 88.7 NA .88
Other arrhythmias
Other supraventricular tachycardia 6 (0.8) 11 (1.5) 1.85 (0.68-5.02) .33
Ventricular tachycardia or fibrillation 9 (1.2) 5 (0.7) 0.55 (0.18-1.66) .42
Other end points
MACEs, in-hospitalg 20 (2.6) 13 (1.7) 0.62 (0.31-1.25) .18
Myocardial infarction 10 (1.3) 10 (1.3) 0.99 (0.41-2.39) .99
Stroke 8 (1.1) 4 (0.5) 0.45 (0.13-1.51) .18
Cardiovascular death 3 (0.4) 0 (0.0) NA .08
Arterial thromboembolism, 30-d 13 (1.7) 5 (0.7) 0.37 (0.13-1.03) .047
Arterial thromboembolism or death, 30-d 27 (3.6) 13 (1.7) 0.44 (0.24-0.86) .01
Total mortality, 30-d 15 (2.0) 8 (1.1) 0.53 (0.23-1.26) .14
Cardiac arrhythmic 0 (0.0) 1 (0.1) NCh .32
Cardiac nonarrhythmic 2 (0.3) 0 (0.0) NCh .16
Vascular 3 (0.4) 0 (0.0) NCh .08
Noncardiovascular 10 (1.3) 7 (0.9) 0.70 (0.27-1.84) .47
Resource utilization, median (IQR), d
Total ICU/CCU stay 2 (1-3) 2 (1-3) NA .38
Total telemetry monitoring 6 (5-7) 6 (5-7) NA .39
Total hospital stay 7 (5-8) 7 (5-9) NA .48
Abbreviations: AF, atrial fibrillation; HR, hazard ratio; ICU/CCU, intensive care unit/coronary care unit; IQR, interquartile range; MACEs, major adverse cardiac events (myocardial
infarction, stroke, or cardiovascular death); NA, not applicable; NC, not calculable; n-3-PUFA, omega-3 polyunsaturated fatty acid; OPERA, Omega-3 Fatty Acids for Prevention
of Post-operative Atrial Fibrillation; OR, odds ratio.
aAll analyses were based on intention-to-treat. Values are ORs estimated using logistic regression for postoperative AF and other arrhythmias and HRs estimated using Cox pro-
portional hazards for other end points such as MACEs.
bDetermined using Pearson 2 (or Fisher exact tests for cells10) for the primary postoperative AF end point, the first 2 secondary postoperative AF end points, and other tachyar-
rhythmias; Poisson regression for the total number of postoperative AF events per patient and the total number of in-hospital days with 1 or more episodes of postoperative AF;
the Wilcoxon rank-sum test for the proportion of in-hospital days free of any postoperative AF and days of resource utilization; and the log-rank test for MACEs, arterial throm-
boembolism, and mortality end points.
cThe median duration of the first postoperative AF episode was 0.92 (IQR, 0.17-1.0) days in the placebo group and 1.0 (0.17-1.0) days in the n-3-PUFA group (Wilcoxon rank-sum
P=.62).
dA total of 661 postoperative AF episodes occurred in 460 patients. Among these episodes, 8.9% were associated with dyspnea, chest pain, or hypotension requiring escalation
of therapy; 76.7% were treated with electrical or pharmacological cardioversion (predominantly amiodarone); 87.4% lasted longer than 1 hour; and 97.9%met 1 or more of these
criteria.
eExcluding atrial flutter and supraventricular tachycardia with some but not all characteristics consistent with AF.
fAmong the 460 patients with postoperative AF. Among all 1516 patients, the corresponding values were 0.8 (1.7) days in the placebo group and 0.8 (1.7) days in the n-3-PUFA
group (P=.93).
gSee eTable 2 for detailed definitions of all events. Analyses of individual MACEs components include all subtypes of events occurring in any patient.
hNot reliably calculable, given few numbers of events.
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Effects of n-3-PUFAs on the pri-
mary end point did not significantly dif-
fer among most prespecified sub-
groups (FIGURE3). Potential interaction
(prespecified=.10) was observed only
by type of cardiac surgery (P=.06 for
interaction), with patients undergo-
ing valve surgery having a trend to-
ward lower risk of postoperative AF
with n-3-PUFA treatment. In post hoc
analyses, risk of postoperative AF with
n-3-PUFA treatment was similar
whether valve surgery was aortic or mi-
tral (eAppendix).
In the predefined surgical popula-
tion (underwent surgery, received at
least 1 dose of study drug), 233 of 723
patients (32.2%) in the placebo group
and 225 of 728 (30.9%) in the n-3-
PUFA group developed postoperative
AF (P=.60). In the further subset of ad-
herent patients (taking 80% of as-
signed study drug), which included 591
of 723 patients (81.7%) assigned to pla-
cebo and 596 of 728 patients (81.9%)
assigned to n-3-PUFAs, 186 (31.5%)
and 178 (29.9%) patients, respec-
tively, developed postoperative AF
(P=.55).
From the time of enrollment to the
morning of cardiac surgery, plasma
phospholipid n-3-PUFA concentra-
tions increased approximately 40% in
the n-3-PUFA group, from 4.65% (SD,
1.44%) to 6.40% (SD, 1.70%) of total
fatty acids, whereas they remained un-
changed in the placebo group (4.65%
[SD, 1.43%] to 4.78% [SD, 1.43%])
(P .001 for change in fatty acid lev-
els by treatment group). Stratified by
actual study drug loading days, phos-
pholipid n-3-PUFA concentrations in
the treatment group increased by 0.47%
of total fatty acids at day 1, by 1.11%
at day 2, by 1.91% at day 3, by 2.55%
at day 4, and by 2.30% at day 5. Ef-
fects of n-3-PUFA treatment on post-
operative AF, however, were not sig-
nificantly different by loading days
(Figure 3).
Compared with patients in the pla-
cebo group, those in the n-3-PUFA
group received significantly fewer
packed red blood cell transfusions, in-
cluding during surgery (P=.002), af-
ter surgery (P= .008), and overall
(P .001) (eTable 5). Other bleeding
indices did not significantly differ by
treatment. Minor adverse events com-
monly seen with fish oil, such as gas-
trointestinal upset, burping, and fish oil
taste, occurred more commonly in the
n-3-PUFA group. Adverse events re-
quiring discontinuation of study drug
and other serious adverse events were
similar between groups (eTable 6).
COMMENT
This large, multinational, double-
blind, placebo-controlled randomized
clinical trial found no evidence that
perioperative n-3-PUFA supplementa-
tion reduced postoperative AF. Re-
sults were similar for various second-
ary end points, among different patient
subgroups, and in various sensitivity
analyses. Major strengths of OPERA in-
clude its large size and large numbers
of events, which achieved anticipated
statistical power. The broad inclusion
criteria and multinational enrollment
support the generalizability of our find-
ings.
In controlled trials lasting weeks
to months, n-3-PUFA supplementa-
tion favorably influences several
physiological pathways related to AF,
including blood pressure, systemic
vascular resistance, heart rate,
inflammation, endothelial function,
left ventricular diastolic function,
myocardial efficiency of oxygen use,
and possibly vagal tone.8 Our design
cannot exclude potential benefits of
much longer durations (eg, weeks to
years) of n-3 PUFA supplementation
for altering systemic physiology and
risk of AF in other clinical contexts.
Such prolonged durations of therapy
would be impractical as a common
preventive measure for most patients
scheduled to undergo cardiac sur-
gery. Based on the known benefits of
n-3-PUFAs on cardiovascular risk
factors and physiologic pathways, a
more promising strategy may be
long-term consumption to reduce the
primary incidence of AF among
ambulatory elderly adults with
hypertension or other risk factors15;
such an approach should be tested in
appropriately designed and powered
clinical trials.
Subgroup analyses did not detect any
difference in efficacy depending on
baseline fish consumption or circulat-
ing n-3-PUFA levels. Observational
studies of fish consumption and coro-
nary heart disease death in generally
healthy populations suggest that some
dietary n-3-PUFAs (approximately 250
mg/d of EPA plus DHA, or about 1-2
fish servings/wk) are better than none
but that greater consumption may not
substantially alter risk further.22 Our
findings do not support such a dose-
response relationship for postopera-
tive AF. Findings were also similar in
other subgroups, except for a sugges-
tion of greater efficacy among patients
undergoing valve surgery. Based on the
multiple subgroups explored, this find-
ing most plausibly results from chance
and should be interpreted cautiously
until evaluated prospectively in future
studies.
Experimental studies suggest that
n-3-PUFAs have antiarrhythmic ac-
tions.23,24 Our findings provide no evi-
dence that short-term n-3-PUFA
supplementation provides clinically rel-
evant antiarrhythmic effects in the acute
setting of cardiac surgery. Further, there
is no consistent evidence that n-3-
PUFAs are effective antiarrhythmic
agents in the context of established
Figure 2. Kaplan-Meier Incidence of
Postoperative Atrial Fibrillation, According to
Treatment Group
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Hazard ratio, 0.96 (95%CI, 0.80-1.15). n-3-PUFA in-
dicates omega-3 polyunsaturated fatty acid.
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Figure 3. Efficacy of Omega-3-PUFAs to Prevent Postoperative Atrial Fibrillation, According to Prespecified Baseline Characteristics
Events, No./Total (%) Favors
n-3 PUFAs
Favors
Placebo
Subgroup
Odds Ratio
(95% CI)
P Value for
InteractionPlacebo n-3-PUFAs
Age,y
<70 0.91 (0.68-1.24)114/483 (23.6)
119/275 (43.3)
105/477 (22.0)
122/281 (43.4)≥70 1.01 (0.72-1.41) .68
Sex
Men 0.97 (0.75-1.26)169/543 (31.1)
64/215 (29.8)
168/551 (30.5)
59/207 (28.5)Women 0.94 (0.62-1.43)
.90
Cardiac valve surgery
No 1.20 (0.86-1.69)84/356 (23.6)
149/371 (40.2)
95/351 (27.1)
132/385 (34.3)Yes 0.78 (0.58-1.05)
.06
Hypertension
No 0.94 (0.57-1.55)41/189 (21.7)
189/563 (33.6)
37/179 (20.7)
188/572 (32.9)Yes 0.97 (0.76-1.24)
.92
NYHA class II-IV
No 0.97 (0.75-1.26)165/556 (29.7)
60/177 (33.9)
162/556 (29.1)
62/185 (33.5)Yes 0.98 (0.64-1.52)
.97
Serum potassium, mmol/L
<4.18 0.94 (0.69-1.29)115/354 (32.5)
110/375 (29.3)
117/375 (31.2)
102/355 (28.7)≥4.18 0.97 (0.71-1.34) .90
Left atrial diameter, mm
<42 0.93 (0.61-1.42)60/242 (24.8)
108/278 (38.9)
56/238 (23.5)
107/277 (38.6)≥42 0.99 (0.70-1.39) .83
Ejection fraction, %
<50 1.10 (0.65-1.87)36/147 (24.5)
194/601 (32.3)
37/141 (26.2)
187/607 (30.8)≥50 0.93 (0.73-1.19) .59
Habitual fish intake, servings/wk
<2 1.14 (0.73-1.78)56/203 (27.6)
20/59 (33.9)
54/178 (30.3)
28/68 (41.2)≥2 1.37 (0.66-2.81) .68
Phospholipid n-3-PUFA level, %
<4 1.27 (0.67-2.42)22/97 (22.7)
58/158 (36.7)
28/103 (27.2)
58/165 (35.2)≥4 0.93 (0.59-1.47) .44
Perioperative medications
β-Blockers
No 0.95 (0.63-1.42)70/232 (30.2)
163/526 (31.0)
65/224 (29.0)
162/534 (30.3)Yes 0.97 (0.75-1.26)
.92
Statins
No 0.94 (0.65-1.35)84/274 (30.7)
149/484 (30.8)
81/276 (29.4)
146/482 (30.3)Yes 0.98 (0.74-1.29)
.87
Amiodarone
No 0.86 (0.67-1.10)177/648 (27.3)
31/85 (36.5)
158/647 (24.4)
34/75 (45.3)Yes 1.44 (0.77-2.72)
.14
ACE inhibitors/ARBs
No 1.02 (0.72-1.43)94/333 (28.2)
139/425 (32.7)
92/322 (28.6)
135/436 (31.0)Yes 0.92 (0.69-1.23)
.67
On-pump time, h:min
<1:36 1.05 (0.75-1.46)92/348 (26.4)
141/379 (37.2)
102/373 (27.4)
125/363 (34.4)≥1:36 0.89 (0.66-1.20) .46
Cross-clamp time, h:min
<1:11 1.12 (0.80-1.56)85/342 (24.9)
148/385 (38.4)
103/382 (27.0)
124/354 (35.0)≥1:11 0.86 (0.64-1.17) .26
233/759 (30.7) 227/757 (30.0)Overall 0.96 (0.77-1.20)
Country
Argentina 0.87 (0.54-1.39)52/171 (30.4) 47/171 (27.5)
116/363 (32.0) 115/365 (31.5)Italy 0.98 (0.72-1.34)
65/224 (29.0) 65/222 (29.3)United States 1.01 (0.67-1.52)
.64
0.25 0.50 1.0 2.0 4.0
Odds Ratio (95% CI)
Study drug loading d (actual)
0 3.25 (0.32-32.7)1/14 (7.1) 4/20 (20.0)
3/21 (14.3) 2/13 (15.4)1 1.09 (0.16-7.59)
89/310 (28.7) 97/330 (29.4)2 1.03 (0.74-1.46)
3 1.21 (0.73-2.00)40/144 (27.8) 45/142 (31.7)
28/63 (44.4) 19/74 (25.7)4 0.43 (0.21-0.89)
72/206 (35.0) 60/179 (33.5)5 0.94 (0.62-1.43)
.28
All characteristics are at enrollment except for cardiac valve surgery (based on actual surgery performed), study drug loading days, perioperative medication use (de-
fined as use at enrollment, on the morning after cardiac surgery, or both), on-pump time, and cross-clamp time. Only patients with complete data on the relevant
stratifying variable were included in each subgroup analysis. Logistic regression was used to determine the odds ratio and 95% CI for the effect of treatment in each
subgroup. The statistical significance of potential interaction was quantified using the Wald test for a multiplicative interaction term (treatment
stratifying variable).
ACE indicates angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; n-3-PUFA, omega-3 polyunsaturated fatty acid; NYHA, New York Heart Association.
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cardiac arrhythmias, such as in pa-
tients with prior ventricular arrhyth-
mias and implantable cardiodefibrilla-
tors or with prior established chronic
or paroxysmal AF.25-31 Early clinical
trials demonstrated that long-term in-
take of fish32 or fish oil33,34 reduced the
risk of cardiac death in patients with re-
cent myocardial infarction, and the
overall evidence from subsequent ex-
periments, observational studies, and
clinical trials continues to point to-
ward a reduction in cardiac death as the
principal cardiovascular benefit of long-
term n-3-PUFA intake.8,9
Prior smaller trials found mixed ef-
fects of perioperative n-3-PUFAs on
postoperative AF.16,35-40 Two studies re-
ported a reduction in postoperative
AF16,38 but were small (40 events
each) and also open-label, ie, neither
placebo-controlled nor double-blind.
Five other small placebo-controlled
trials found no significant effects of n-3-
PUFAs on postoperative AF,35-37,39,40 but
the small numbers of events in each
study (range, 24-91 events each) lim-
ited statistical power and made it dif-
ficult to draw strong conclusions about
absence of effects. The OPERA trial,
comprising more patients and AF events
than all of these prior trials combined,
provides the most definitive answer to
this important research question. The
variation in findings of prior small trials
and especially studies without pla-
cebo control highlights the impor-
tance of conducting large, appropri-
ately powered, placebo-controlled trials
such as the present study.
Many drugs have been tested but
failed to prevent postoperative AF; oth-
ers, such as -blockers and amioda-
rone, only partly reduce risk.2 The
effects of cardiac surgery on neurohor-
monal, oxidative, and inflammatory
activation and atrial remodeling may
simply be too great to be countered by
most drugs, including n-3-PUFAs. Post-
operative AF remains an intractable
and enigmatic complication of sur-
gery. Our findings and those of prior
studies highlight the need for meticu-
lous investigation of the underlying
physiological, structural, and molecu-
lar underpinnings of postoperative AF
to allow novel targeted preventive and
therapeutic interventions.
The secondary end points of arte-
rial thromboembolism and arterial
thromboembolism or death occurred
less frequently in the n-3-PUFA group.
However, numbers of events were
small, and these findings should be
viewed with caution until confirmed in
future studies. Supplementation with
n-3-PUFAs was well tolerated in this
large and heterogeneous population of
patients undergoing cardiac surgery,
and there was no evidence that n-3-
PUFA supplementation was unsafe.
Although there have been theoreti-
cal concerns that n-3-PUFAs could ag-
gravate bleeding, no increased hemor-
rhagic risk was seen across a variety of
indices. Patients in the n-3-PUFA group
required significantly fewer transfu-
sions; this finding may be attributable
to chance, but it further supports ab-
sence of increased bleeding risk. These
results confirm and extend the find-
ings of prior smaller trials that found
no evidence that n-3-PUFA supplemen-
tation increased clinical bleeding fol-
lowing cardiac surgery,16,35-39 surgical ar-
terial endarterectomy,41,42 or coronary
angioplasty.43 More than half of the pa-
tients in OPERA were taking aspirin or
other anticoagulants before cardiac sur-
gery, similar to other trials in which n-3-
PUFAs were combined with aspirin or
warfarin following cardiac surgery with-
out any excess clinical bleeding.44
This study has limitations that should
be considered. Current best-practice
guidelines for preventing postopera-
tive AF were recommended to all cen-
ters, which could have reduced the in-
fluence of any additional therapy on risk
of postoperative AF. As would be re-
flected in clinical practice, patients were
identified and assigned to receive n-3-
PUFAs over varying durations rang-
ing from 2 to 5 days prior to surgery.
Shorter durations could have been less
effective. Subgroup analyses, how-
ever, did not detect significantly greater
risk reduction with greater numbers of
days of preoperative n-3-PUFAs, pro-
viding little evidence that longer dura-
tions of loading make a difference, at
least up to 5 days. The dose of n-3-
PUFAs may have been too low to pro-
duce a benefit, and we did not have
available data on achieved myocardial
levels of n-3-PUFAs. Yet circulating n-3-
PUFAs have systemic effects that could
reduce risk of AF,8 and phospholipid
n-3-PUFA levels increased by an aver-
age of 40% by the time of surgery, pro-
viding novel evidence that even short-
term supplementation significantly
influences circulating levels. Adher-
ence with study drug was high but not
perfect. Our analysis restricted to ad-
herent patients, however, was consis-
tent with the main findings.
In summary, perioperative n-3-
PUFA supplementation did not re-
duce postoperative AF in this large, ad-
equately powered, placebo-controlled,
randomized multinational trial.
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MS;Department of Surgical Sciences, Division of Car-
diac Surgery, University of Torino, Torino (101 pa-
tients enrolled):Mauro Rinaldi, MD (center PI), Ste-
fano Salizzoni, MD, Giovanni Marchetto, MD; GVM
Care & Research—E.S. Health Science Foundation,
Cotignola (62 patients enrolled):Mauro Lamarra,MD
(center PI), Marco Pagliaro, MD, Maria Cristina Jori,
MD, Luca Dozza, MSB, Simone Calvi, MD; Azienda
Ospedaliera Ordine Mauriziano di Torino, Osped-
ale Mauriziano Umberto I, Torino (30 patients en-
rolled): Riccardo Casabona, MD (center PI), Edoardo
Zingarelli, MD, Roberto Flocco, MD; Unit of Cardiac
Surgery, Humanitas Clinical andResearchCenter, Roz-
zano (29 patients enrolled): Alessandro Eusebio, MD
(center PI), Giuseppe Raffa,MD,Giuseppe Tarelli,MD;
Centro Cardiologico Monzino I.R.C.C.S, Milano (24
patients enrolled):Alessandro Parolari,MD, PhD (cen-
ter PI), Laura Cavallotti, MD, Veronica Miyasoe-
dova, MD, PhD, Federica Laguzzi, BS; GVM Care &
Research—E.S. Health Science Foundation, Lecce (19
patients enrolled): Renato Gregorini, MD (center PI),
Federica Mangia, MD; Fondazione I.R.C.C.S. Poli-
clinico S. Matteo, Pavia (15 patients enrolled): Fab-
rizio Gazzoli, MD (center PI), Eliana Raviola, MD,Ma-
rio Viganò, MD; AziendaOspedaliero—Universitaria
Santa Maria della Misericordia, Udine (12 patients
enrolled):Ugolino Livi,MD (center PI), Esmeralda Pom-
pei, MD; Ospedale San Bortolo, Vicenza (5 patients
enrolled): Loris Salvador, MD (center PI), Nicola La-
mascese, MD, Massimo Bilotta, MD; Niguarda Ca’
Granda Hospital, Department of Cardiac Surgery,Mi-
lan (3 patients enrolled): Luigi Martinelli, MD (cen-
ter PI), AldoCannata,MD.USCenters:Vanderbilt Uni-
versity, Nashville, Tennessee (99 patients enrolled):
Nancy J. Brown,MD (center PI), John Byrne,MD,Mar-
zia Leacche, MD, Michael R. Petracek, MD, Stephen
K. Ball, MD;University of Texas SouthwesternMedi-
cal Center Dallas (74 patients enrolled): Michael E.
Jessen,MD (center PI),MaryWeyant, RN, BSN;Wash-
ington University, St Louis, Missouri (66 patients en-
rolled): Ralph J. Damiano Jr, MD (center PI); Rhode
Island Hospital, Providence (61 patients enrolled):
Frank W. Sellke, MD (center PI), Arun K. Singh, MD,
Mary Jane McDonald, RN, MS; Brigham and Wom-
ens Hospital, Boston,Massachusetts (54 patients en-
rolled): R. Morton Bolman III, MD (center PI), Debra
A. Conboy, RN, BSN, Anne Burgess, RN, MSHI, BSN;
Emory Healthcare, Atlanta, Georgia (45 patients en-
rolled): JohnD. Puskas,MD (center PI); SanfordHealth,
Sanford University of South Dakota Medical Center,
Sioux Falls (31 patients enrolled): John Vander-
Woude Jr, MD (center PI), Maria C. Bell, MD (center
PI); University of Arizona and Tucson Medical Cen-
ter, Tucson (9 patients enrolled): Gulshan Sethi, MD
(center PI); State University of New York Downstate,
Brooklyn (7 patients enrolled):Daniel C. Lee,MD (cen-
ter PI). Argentina Centers: Fundacio´n Favaloro, Bue-
nos Aires (180 patients enrolled): Roberto Rene´ Fa-
valoro, MD (center PI), Alejandro Rube´n Hershson,
MD, Julio Ce´sar Figal, MD;Hospital Italiano, Buenos
Aires (59 patients enrolled): Alberto Domenech, MD
(center PI),MarceloHalac,MD;Hospital Espan˜ol, Bue-
nos Aires (44 patients enrolled): Liliana Noemı´ Nico-
losi,MD (center PI), ClaudioGabrielMoro´s,MD,Marı´a
del Carmen Rubio, MD, Richard Fuentes Sua´rez, MD;
Instituto de Cardiologia de Corrientes, Corrientes (33
patients enrolled):Horacio Cacheda, MD (center PI),
Juan Pablo Casal, MD;Clinica yMaternidad de Suizo,
Buenos Aires (23 patients enrolled): Juan Carlos Me-
drano,MD (center PI),Marı´a Carla Cucurell,MD, Flor-
encia Scattini, MD; Instituto Fundacio´n de Lucha con-
tra las Enfermedades Neurolo´gicas en la Infancia,
Buenos Aires (3 patients enrolled): Carlos Nojek, MD
(center PI), Mariano Camporrotondo, MD.
Statistical Analyses: Statistical analyses were per-
formed by Dr Mozaffarian at Harvard University and
by Ms Silletta and Marco Scarano at Consorzio Ma-
rio Negri Sud, Santa Maria Imbaro, Italy. No separate
compensation or funding was received for conduct-
ing the analyses.
Online-Only Material: The eAppendix, eTables 1-6,
and the eFigure are available at http://www.jama
.com.
Additional Contributions: Data and Safety Monitor-
ing Board: David M. Herrington, MD, MHS (chair)
(Wake Forest University School ofMedicine,Winston-
Salem, North Carolina),MariaMori Brooks, PhD (Uni-
versity of Pittsburgh, Pittsburgh, Pennsylvania), Raf-
faele De Caterina,MD, PhD (Università degli Studi “G.
d’Annunzio,”Chieti, Italy), Marc Gillinov,MD (Cleve-
landClinicMainCampus, Cleveland,Ohio), Luigi Pade-
letti, MD (University of Florence, Florence, Italy), Fa-
bio Pellegrini, MS (Consorzio Mario Negri Sud, Santa
Maria Imbaro, Italy), Barbra Bluestone Rothschild,MD
(The University of North Carolina at Chapel Hill), Fer-
nando Rubinstein,MD,MPH (IECS—Instituto de Efec-
tividad Clı´nica y Sanitaria, Buenos Aires, Argentina).
Biomarker and Cognitive Decline Ancillary Study: Pho
Q. Diep, BS, Junitta B. Guzman, MS (Fred Hutchin-
son Cancer Research Center, Seattle, Washington).
MainData Coordinating Center, ConsorzioMarioNe-
gri Sud, Santa Maria Imbaro, Italy: Laura Palmarini,
PharmD, Stefania Sacchetti, PharmD, Anna V. Flam-
minio, Rosamaria Marfisi, MS, Marco Scarano, MS.
US Clinical Coordinating Center, Harvard School of
Public Health, Boston, Massachusetts: Ashkan Af-
shin, MD, MPH, Hongyan Huang, MS, PhD, Fadar
Otite,MD,MS. Italy Centers:Ospedali Riuniti di Ber-
gamo, Bergamo:Marilisa Ambrosio, BS, Annarita Lin-
cesso, BS, Laura Pezzoli, BS;Ospedali Riuniti and Uni-
versity of Trieste, Trieste:Marco Anzini, MD, Cosimo
Carriere, MD, Rita Belfiore, MD; Department of Sur-
gical Sciences, Division of Cardiac Surgery, Univer-
sity of Torino:Guglielmo Fortunato,MD, Augusto Pel-
legrini, MD, Eliana Raviola, MD, Vincenzo Reale, MD,
Paolo Sorrentino, MD; GVM Care & Research—E.S.
Health Science Foundation, Cotignola: Giulia Schia-
vina, MSB, Monica Negrosanti, BS; Azienda Osped-
aliera Ordine Mauriziano di Torino, Ospedale Maur-
iziano Umberto I, Torino: Giacomo Ravenni, MD;
Centro Cardiologico Monzino, I.R.C.C.S, Milano:
Franco Moro, Marta Brambilla, PhD, Cristina Nava,
MD, PhD, Monica Giroli, BS, Andrea Daprati, MD,
Marco Gennari, MD, Dennis Ezra Puma Cusihua-
man, MD; GVM Care & Research—E.S. Health Sci-
ence Foundation, Lecce: Barbara Spagnolo, PhD,Mi-
chela Francia, MS, Maurizio Stanca, MS; Fondazione
I.R.C.C.S. Policlinico S. Matteo, Pavia: Marco Paris,
MD, Daniele Berwick, MD, Bruno Lusona, MD, Ni-
coletta Castiglione, MD; Azienda Ospedaliero—
Universitaria Santa Maria della Misericordia, Udine:
Marzia De Biasio,MD, Cristian Daffarra,MD;USCen-
ters: Vanderbilt University, Nashville, Tennessee:
Rashid Ahmad,MD, Carol A.Meisch, RN, BSN, CCRP,
Simon Maltais, MD, Jorge Balaguer, MD; Washing-
ton University, St Louis, Missouri: Tamara Donahue,
RN, BSN; Emory Healthcare, Atlanta, Georgia: Rob-
ert A. Guyton, MD, Vinod Thourani, MD, Michael
Halkos, MD, Omar Lattouf, MD, Kim T. Baio, MSN,
Samatha R. Levine, RN, Zachary E. Pitts, RN; Sanford
Health, Sanford University of South Dakota Medical
Center, Sioux Falls: Kathy Janssen, Marilyn Ruhl-
man, RN, BSN, PA-C, CCRP;University of Arizona and
TucsonMedical Center, Tucson: Sarah Sharp, BS; State
University of New York Downstate, Brooklyn: Kristy
Pang, BS, RN. Argentina Centers: Fundacio´n Fa-
valoro, Buenos Aires:Matı´as Nicola´s Mungo, SC, Ada
Liz Servia´n, RN; Hospital Italiano, Buenos Aires: Ro-
berto Battellini, MD, RicardoMarenchino,MD, Vadim
Kotowicz, MD, Vicente Cesa´reo, MD, Ricardo Sa´n-
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chez,MD, Veronica Romero, SC, Silvia Avila, SC;Hos-
pital Espanol, Buenos Aires: FabianDonnini,MD, Leti-
cia Biancospino, BS; Instituto de Cardiologia de
Corrientes, Corrientes: Romina Laurino, MD, Ro-
dolfo Portalea, RN.
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